Replies to post #1265 on Israel-Medical-Healthcare

[midastouch017]

if approved, is likely to be widely prescribed. In the future, new Kitov combination drugs would follow KIT-302's pattern of low development risk and efficient regulatory pathways, returning a quicker than usual return on investment.